Opthea Ltd. is a clinical stage biopharmaceutical company, which engages in the development of biological therapeutics for the treatment of progressive retinal diseases. The company is headquartered in Melbourne, Victoria. The firm is engaged in developing novel therapies to address the unmet need in the treatment of prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Its lead product candidate, sozinibercept (OPT-302), is being evaluated in two pivotal Phase 3 clinical trials for use in combination with standard-of-care anti-VEGF-A monotherapies for the treatment of wet AMD and DME. The firm has also manufactured OPT-302 for use in Phase III clinical trials, conducts activities to support the commercialization of the product and expanded its management team in the United States to facilitate broader oversight and execution of its Phase III program. Its development activities are based on an intellectual property portfolio covering key targets (Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3).
Follow-Up Questions
CKDXF 주식의 가격 성능은 어떻습니까?
CKDXF의 현재 가격은 $0이며, 전 거래일에 decreased 0% 하였습니다.
Opthea Ltd의 주요 사업 주제나 업종은 무엇입니까?
Opthea Ltd은 Biotechnology 업종에 속하며, 해당 부문은 Health Care입니다
Opthea Ltd의 시가총액은 얼마입니까?
Opthea Ltd의 현재 시가총액은 $0입니다
Opthea Ltd는 매수, 매도, 아니면 보유해야 하나요?
월스트리트 분석가들에 따르면, 5명의 분석가가 Opthea Ltd에 대한 분석 평가를 실시했으며, 이는 0명의 강력한 매수, 1명의 매수, 3명의 보유, 4명의 매도, 그리고 0명의 강력한 매도를 포함합니다